Repligen to Report First Quarter 2025 Financial Results
Rhea-AI Summary
Repligen (NASDAQ:RGEN) has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025. The company will release its earnings press release before market opening, followed by a conference call at 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2025.
The conference call will be accessible via toll-free numbers: (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. A webcast will also be available through the company's Investor Relations website. Replay options include dial-in numbers (877) 344-7529 (US), (855) 669-9658 (Canada), and (412) 317-0088 (international) with passcode 6386085.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RGEN declined 0.50%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ET
WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025.
The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 6386085.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com
FAQ
When will Repligen (RGEN) report Q1 2025 earnings?
How can investors access Repligen's (RGEN) Q1 2025 earnings call?
What is the replay passcode for Repligen's (RGEN) Q1 2025 earnings call?
What period will Repligen's (RGEN) Q1 2025 financial results cover?
